(IHE) iShares U.S. Pharmaceuticals - Ratings and Ratios
Pharmaceuticals, Manufacturers, Prescription Drugs, Over-The-Counter Drugs, Vaccines
Description: IHE iShares U.S. Pharmaceuticals October 23, 2025
The iShares U.S. Pharmaceuticals ETF (NYSE ARCA:IHE) tracks an index of U.S. companies that develop, manufacture, or market prescription drugs, over-the-counter medicines, and vaccines. The fund is required to hold at least 80 % of its net assets in the underlying securities and may allocate up to 20 % to derivatives, cash, or cash equivalents; it is classified as a non-diversified ETF.
Key quantitative points (as of the most recent filing) include an expense ratio of 0.43 %, total assets of roughly $1.2 billion, and a top-10 holding concentration of about 30 % of assets, dominated by large caps such as Pfizer, Johnson & Johnson, and Merck. The sector’s growth outlook is driven by an aging U.S. population (projected to increase the 65+ cohort by ~10 % over the next decade), accelerating demand for specialty biologics, and a regulatory environment that is gradually shifting toward faster approvals for breakthrough therapies, though pricing pressure from Medicare and pharmacy benefit managers remains a headwind.
For a deeper, data-rich analysis of IHE’s risk-adjusted performance and how its exposure aligns with macro-level health-care trends, you might explore the ValueRay platform.
IHE ETF Overview
| Market Cap in USD | 598m |
| Category | Health |
| TER | 0.40% |
| IPO / Inception | 2006-05-01 |
IHE ETF Ratings
| Growth Rating | 57.4% |
| Fundamental | - |
| Dividend Rating | 56.1% |
| Return 12m vs S&P 500 | -7.94% |
| Analyst Rating | - |
IHE Dividends
| Dividend Yield 12m | 1.48% |
| Yield on Cost 5y | 2.27% |
| Annual Growth 5y | 12.46% |
| Payout Consistency | 92.3% |
| Payout Ratio | % |
IHE Growth Ratios
| Growth Correlation 3m | 83.8% |
| Growth Correlation 12m | 37.4% |
| Growth Correlation 5y | 76.6% |
| CAGR 5y | 10.72% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.67 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.41 |
| Sharpe Ratio 12m | 1.14 |
| Alpha | -3.81 |
| Beta | 0.650 |
| Volatility | 13.74% |
| Current Volume | 103.4k |
| Average Volume 20d | 33.5k |
| Stop Loss | 73.6 (-3.1%) |
| Signal | 1.22 |
What is the price of IHE shares?
Over the past week, the price has changed by +1.35%, over one month by +4.70%, over three months by +16.06% and over the past year by +11.77%.
Is iShares U.S. Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IHE is around 74.39 USD . This means that IHE is currently overvalued and has a potential downside of -2.08%.
Is IHE a buy, sell or hold?
What are the forecasts/targets for the IHE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 82.9 | 9.1% |
IHE Fundamental Data Overview October 20, 2025
Beta = 0.65
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 598.3m USD (598.3m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 598.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 598.3m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.41% (E(598.3m)/V(598.3m) * Re(8.41%) + (debt-free company))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IHE ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle